SELANGOR, November 8, 2023 - Roche (Malaysia) Sdn Bhd, the pharmaceutical division and Roche Diagnostics (M) Sdn Bhd, the diagnostics division, recently signed a Memorandum of Understanding (MoU) with Premier Integrated Labs (PILs) in its bid to increase awareness and understanding of Comprehensive Genomic Profiling (CGP) and improve patient access to CGP for patients in Malaysia.
Comprehensive Genomic Profiling (CGP) tailors personalised cancer treatment for the patients. With a single test, CGP can analyse a broad panel of genes that is known to drive cancer growth. This type of testing produces comprehensive patient reports with broad and deep assessments of the possible underlying cancer drivers.1,2
Heng Chai Yin, General Manager of Roche Diagnostics (M) Sdn. Bhd. shared, “At Roche, we have a passion for innovation and we strive to improve patient access in Malaysia as healthcare that is built on people’s needs, strong data and clinical insights is healthcare that saves lives.” She added that Roche understands the importance the role cancer genomics can play and is actively working towards increasing the awareness and understanding of CGP, staying true to Roche’s vision of continuously innovating diagnostics, shaping healthcare and changing lives.
She further added, “Our partnership with Premier Integrated Labs is a testament to the power of collaboration and a testament to our shared values, aspirations, and the belief that together, we can shape a brighter future for a better Malaysia.”
Mr. Hareeff Muhammed, Chief Executive Officer of Premier Integrated Labs expressed his enthusiasm stating, “We are thrilled to formalise our partnership with Roche, marking a landmark moment that holds the potential to reshape healthcare in Malaysia. Our commitment to raising awareness about CGP and ensuring broader access to this innovative medical advancement reinforces our dedication to personalised medicine, unlocking the power of genetics for more precise, tailored treatments.”
He further emphasised, “Together with Roche, we aspire to make CGP accessible to all patients, transcending socio-economic boundaries and geographic constraints. This partnership signifies our shared vision for a healthier and brighter future in Malaysia healthcare.”
“We are committed to evolving the standards of care in cancer and helping patients live longer, better lives. We also want to deliver the best care for each person by shifting away from a one-size-fits all approach to personalising treatment for each cancer patient,” said Deepti Saraf, General Manager of Roche (Malaysia) Sdn. Bhd. She also added that the signing of this MoU represents a significant milestone in Roche’s commitment to advancing healthcare in Malaysia and beyond. “We look forward to partnerships similar to this in the future, as we are committed to ensuring that patient and population health can be leapfrogged to personalised care,” Deepti added.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit
Roche has been present in Malaysia since the 1950s, when the sales and distribution of products was managed by a third party distributor. Since then, Roche has established its operations to include Roche (Malaysia) Sdn. Bhd., the pharmaceutical business; Roche Diagnostics (Malaysia) Sdn. Bhd., the diagnostics business and Roche Services (Asia Pacific) Sdn. Bhd. (also referred to as Roche Services & Solutions APAC). With a total staff strength of over 1,000, Roche has grown into one of the leading healthcare companies in Malaysia that provides holistic healthcare solutions to healthcare practitioners and patients. For more information, please visit
All trademarks used or mentioned in this release are protected by law.
About Premier Integrated Labs
Premier Integrated Labs Sdn. Bhd. is part of IHH Healthcare, one of the world’s largest healthcare providers. It runs 33 laboratories throughout Malaysia, with more than 24 million tests being performed each year.
Premier Integrated Labs provides a comprehensive range of quality diagnostics and analytical laboratory testing services to referring medical practitioners, including general practitioners and specialist doctors, from medical clinics and medical centers to large tertiary hospitals in Malaysia.
The company has established and effectively maintained a Quality Management System based upon the International Organization for Standardization (ISO) 9001:2000 to ensure a high standard of Total Quality Healthcare delivery to its clients. Over the years, it has also successfully been accredited with the College of American Pathologists (CAP), ISO 15189, Malaysian Society for Quality in Health (MSQH), and Joint Commission International (JCI) alongside and in tandem with IHH Healthcare Malaysia’s group of hospitals nationwide. Premier Integrated Labs applies strict quality control in its operations and participates extensively in local and overseas External Assurance Schemes. This is to ensure that the high-quality standards expected by both management and clients are fully attained and maintained.
Being amongst Asia’s largest integrated private healthcare providers operating in Malaysia, Premier Integrated Labs is committed to continuously improving its services to meet current and future healthcare needs by keeping abreast with the latest technology reflected in the ever-expanding comprehensive range of pathological tests being offered.
For further information on Premier Integrated Labs, please contact the Marketing Communications Unit at [email protected]
For media enquiries, please contact:
Siddhattha Chong, Senior PR Consultant, Elliot & Co
+6011-2302 3790 / [email protected]
Jonathan Nelson, Senior PR Consultant, Elliot & Co
+60 18-282 4379 / [email protected]
M-MY-00001788-11-2023
Expires: 06-11-2025 unless superseded by a newer version.
Reference:
1. Comprehensive Genomic Profiling in Predictive Testing of Cancer at
2. Foundation Medicine. (n.d.). Why comprehensive genomic profiling?
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.